For adults and children with hemophilia A
Twice-weekly dosing can mean fewer infusions each week.† Ask your doctor if twice-weekly dosing is right for you.
FDA approved for dosing 2 to 3 times a week.
ZERO median annualized spontaneous bleeds* were reported in clinical trials for children and adults regardless of dosing schedule.
Zero bleeds (median AsBR*) regardless of age or dosing schedule in clinical trials.
*AsBR=annualized spontaneous bleeding rate.
The safety of AFSTYLA was shown in 258 previously treated children, adolescents, and adults over 19,545 exposure days.
Zero inhibitors in a clinical trial of 258 previously treated patients.
Formation of inhibitors to Factor VIII has been reported following use of AFSTYLA.†
†Previously untreated patients may be at greater risk for development of inhibitors.
*AsBR=annualized spontaneous bleeding rate.
†Previously untreated patients may be at greater risk for development of inhibitors.
Sign up today.
Use these tools to help you decide.
CSL Behring makes it easy to start on AFSTYLA. You’ll also have access to comprehensive support services that can make a meaningful difference in the lives of people with bleeding disorders.
Call AFSTYLA ConnectSM at 1-800-676-4266 to get detailed information about the services available to you.
After more than 30 YEARS of experience in bleeding disorders, CSL Behring remains committed to developing innovative therapies for the people who need them